-
Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy
the T2B! immunity against SARS-CoV-2 study group, Schreurs, C. R. G., van der Pol, W. L., Goedee, H. S., Verstegen, N. J. M. & T2B! immunity against SARS-CoV-2 study group, Sept 2024, In: Journal of allergy and clinical immunology. 154, 3, p. 754-766.e7Research output: Contribution to journal › Article › Academic › peer-review
-
T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination
T2B! immunity against SARS-CoV-2 study group, Verstegen, N. J. M., Hagen, R. R., Kuijper, L. H., Ashhurst, T., Palomares Cabeza, V., Steenhuis, M., Duurland, M. C., Jongh, R. D., Schoot, C. E. V. D., Konijn, V. A. L., Mul, E., Kedzierska, K., van Dam, K. P. J., Stalman, E. W., Boekel, L., Wolbink, G., Tas, S. W., Killestein, J. & Rispens, T. & 27 others, , Sept 2024, In: Journal of Neurology, Neurosurgery and Psychiatry. 95, 9, p. 855–864 jnnp-2023-332224.Research output: Contribution to journal › Article › Academic › peer-review
-
mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8+ T cell responses
T2B! immunity against SARS-CoV-2 study group, van Ham, S. M., ten Brinke, A., Duurland, M. C., Konijn, V. A. L., Hagen, R. R., Kuijper, L. H., Wieske, L., van Dam, K. P. J., Stalman, E. W., Steenhuis, M., Geerdes, D. M., Kragten, A. H. M., Menage, C., Koets, L., Veldhuisen, B., Verstegen, N. J. M., van der Schoot, C. E., van Esch, W. J. E. & D'Haens, G. R. A. & 7 others, , 1 Apr 2024, In: Journal of autoimmunity. 144, 13 p., 103175.Research output: Contribution to journal › Article › Academic › peer-review
- All publications
